VENTANA MMR RxDx Panel
Ventana Medical Systems, Inc. (Roche Tissue Diagnostics) · Decision date Aug 17, 2021
What did the FDA approve?
The FDA database entry for P210001 records an approval decision dated August 17, 2021 for the VENTANA MMR RxDx Panel. The stated purpose is use as a companion diagnostic to identify patients with solid tumors whose DNA mismatch repair status is deficient, for potential treatment with JEMPERLI.
The entry classifies the device as an immunohistochemistry test for DNA mismatch repair protein assay under product code QNH, with Ventana Medical Systems, Inc. listed as the applicant. The source statement does not include supplement type or supplement reason fields, so no further detail about the regulatory pathway or scope of the original PMA is available in the supplied record.
FDA approval order statement
Approval for the Ventana MMR RxDx Panel as a CDx for identifying patients with solid tumors with dMMR status who may benefit from treatment with JEMPERLI.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Pathology
- Decision date
- Aug 17, 2021
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P210001
- Regulatory pathway
- Premarket approval application
- Product code
- QNH
- Decision code
- APPR
- Decision date
- Aug 17, 2021
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Immunohistochemistry test, DNA mismatch repair (MMR) Protein assay.
- Product code
- QNH
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P210001 received
Application receipt date recorded by FDA.
P210001 · FDA decision
APPR
P210001/S016 · Related supplement
VENTANA MMR RxDx Panel
Timeline entries are records held by MedtechLedger for P210001. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P210001
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
VENTANA MMR RxDx PanelP210001/S016 | Ventana Medical Systems, Inc. (Roche Tissue Diagnostics) | PMA supplement | Oct 8, 2026 | FDA |
Explore the linked device profile
Other records with product code QNH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
VENTANA MMR RxDx PanelP200019/S014 | Ventana Medical Systems | PMA supplement | Oct 8, 2026 | FDA |
MMR IHC Panel pharmDx (Dako Omnis)P250004/S001 | Agilent Technologies, Inc. | PMA supplement | Sep 11, 2026 | FDA |
| Agilent Technologies, Inc. | PMA approval | Aug 15, 2025 | FDA | |
VENTANA MMR RxDx PanelP200019 | Ventana Medical Systems | PMA approval | Apr 22, 2021 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Ventana Medical Systems, Inc. (Roche Tissue Diagnostics)
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1910 E. Innovation Park Dr., Tucson, AZ, 85755
Sources and methodology
- Original FDA record: P210001
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

